Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 44(6): 635-638, Nov.-Dec. 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1420517

ABSTRACT

Objective: Clozapine is a second-generation antipsychotic indicated for treatment-resistant schizophrenia. Studies in several countries have shown a low rate of clozapine use despite the fact that approximately 30% of schizophrenia cases are treatment-resistant. In Brazil, few studies have addressed the frequency and variety of antipsychotic use in individuals diagnosed with schizophrenia (ICD F20). The objective of this study was to measure the rates of clozapine use in this population in the last decade using Brazilian Ministry of Health data. Methods: Prescriptions made between 2010 and 2020 in all 26 states and the Federal District registered at the Outpatient Information System Database from the Brazilian Health System (SIASUS) were evaluated. Results: A total of 25,143,524 prescriptions were recorded in this period, with clozapine representing 8.86% of all antipsychotics. The most frequently prescribed antipsychotic for patients with schizophrenia was olanzapine (35.8%), followed by quetiapine (27.5%). From 2010 to 2020, the rate of clozapine prescriptions in Brazil increased from 7.2% to 10.9%. Conclusions: Despite a slight increase in prescriptions in the last decade, clozapine is still underutilized in Brazil.

2.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 44(1): 26-34, Jan.-Feb. 2022. tab
Article in English | LILACS-Express | LILACS | ID: biblio-1360175

ABSTRACT

Objective: To test the hypothesis that genetic variations of cannabinoid receptors contribute to the pathophysiology of cognitive deficits in schizophrenia. Methods: In this genetic association case-control study, cannabinoid receptor polymorphisms CNR1 rs12720071 and CNR2 rs2229579 were tested for association with neurocognitive performance in 69 patients with schizophrenia and 45 healthy controls. Neurocognition was assessed by the Brief Assessment of Cognition in Schizophrenia (BACS). Results: We found a consistent association between CNR1 rs12720071 polymorphism and the cognitive performance of patients in several cognitive domains. Patients with C/C polymorphism presented significantly worse performance in motor speed, verbal fluency, attention/processing speed and reasoning/problem solving. Conclusion: Although limited, our data support the hypothesis that CNR1 variations may be associated with the pathogenesis of cognitive deficits of schizophrenia.

3.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 44(1): 74-80, Jan.-Feb. 2022. graf
Article in English | LILACS-Express | LILACS | ID: biblio-1360176

ABSTRACT

The notion that schizophrenia is a neuroprogressive disorder is based on clinical perception of cumulative impairments over time and is supported by neuroimaging and biomarker research. Nevertheless, increasing evidence has indicated that schizophrenia first emerges as a neurodevelopmental disorder that could follow various pathways, some of them neuroprogressive. The objective of this review is to revisit basic research on cognitive processes and neuroimaging findings in a search for candidate keys to the intricate connections between neurodevelopment and neuroprogression in schizophrenia. In the complete panorama, schizophrenia is a neurodevelopmental disorder, possibly associated with an additional burden over the course of the disease through pathologically accelerated aging, and cognitive heterogeneity may explain the different trajectories of each patient.

4.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 44(1): 21-25, Jan.-Feb. 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1360182

ABSTRACT

Objective: Clozapine is underprescribed due to neutropenia risk. Blood tests every 3 months in those on continuous treatment for > 1 year who have never had an absolute neutrophil count (ANC) < 2,000/µL has been proposed as a monitoring strategy; however, there are no South American data to support this recommendation. This study sought to investigate whether clozapine use and other variables could explain the occurrence of ANC < 1,000/µL in patients with severe mental disorders. Methods: A total of 5,847 subjects were included, 1,038 on clozapine. We performed a Cox regression considering the outcome as ANC < 1,000/µL at any time point. Predictors were sex, age, ethnicity, clozapine use, ANC > 2,000/µL during the first year of blood monitoring, and presence of a severe medical condition. Results: In the Cox regression model, ethnicity (white) (hazard ratio [HR] 0.53; 95%CI 0.29-0.99, p < 0.05) and ANC > 2,000/µL (HR 0.04; 95%CI 0.01-0.10, p < 0.001) were protective factors, while presence of a severe medical condition (HR 69.35; 95%CI 37.45-128.44, p < 0.001) was a risk factor for ANC < 1,000/µL. Other variables were not significant, including clozapine use (HR 1.33; 95%CI 0.74-2.39, p > 0.05). Conclusions: These findings suggest that clozapine does not increase the risk of neutropenia in subjects with ANC > 2,000/µL during the first year of use and in the absence of a severe medical condition. These results could help guide clinical and public-health decisions regarding clozapine blood monitoring guidelines.

5.
Trends psychiatry psychother. (Impr.) ; 40(4): 277-284, Oct.-Dec. 2018. tab, graf
Article in English | LILACS | ID: biblio-979442

ABSTRACT

Abstract Introduction: Bipolar disorder (BD) is a debilitating mood condition that affects approximately 1.3% of people worldwide, although some studies report up to 3.9% lifetime prevalence and 4-6% in adults when broad diagnostic criteria are applied. Objective: To compare differences in total white matter (WM), corpus callosum (CC) and total gray matter (GM) volumes in patients with type I BD at early and late stages compared with controls. Methods: Fifty-five subjects were enrolled in this study protocol. The double case-control design included 14 patients with BD at early stage; 15 patients at late stage; and their respective matched controls (14 and 12 subjects). Results: CC and total WM volumes were significantly smaller in patients with BD at early and late stages vs. controls. There was no difference for total GM volume in the early stage group, but in patients at late stage total GM volume was significantly smaller than in controls. The total GM volume reduction in patients at late stage is in agreement with the neuroprogression theory of BD. The reduction of WM volumes in total WM and in the CC at early and late stages supports the possibility that an early demyelination process could occur underlying the clinical manifestation of BD. Conclusion: Our findings may direct to the investigation of WM abnormalities in populations at high risk to develop BD, perhaps as early biomarkers before the overt syndrome.


Resumo Introdução: O transtorno do humor bipolar (THB) é uma condição debilitante que afeta aproximadamente 1,3% das pessoas em todo o mundo, embora alguns estudos relatem uma prevalência acumulada de até 3,9% e de 4-6% em adultos quando os critérios diagnósticos mais abrangentes são aplicados. Objetivo: Comparar as diferenças nos volumes totais de substância branca (SB), corpo caloso (CC) e volume total de substância cinzenta (SC) em pacientes com THB tipo I em estágios iniciais e tardios em comparação com controles. Métodos: Cinquenta e cinco sujeitos foram incluídos neste protocolo de estudo. O desenho de caso com duplo controle incluiu 14 pacientes com THB em estágio inicial; 15 pacientes com THB em fase tardia; e seus respectivos controles correspondentes (14 e 12 sujeitos). Resultados: Os volumes do CC e total de SB foram significativamente menores nos pacientes com THB nos estágios iniciais e tardios vs. controles. Não houve diferença para o volume total de SC no grupo em estágio inicial, mas em pacientes em fase tardia o volume total de SC foi significativamente menor do que nos controles. A redução do volume total de SC em pacientes em fase tardia está de acordo com a teoria da neuroprogressão do THB. A redução dos volumes de SB em SB total e no CC em fases precoces e tardias suporta a possibilidade de que um processo de desmielinização precoce poderia ocorrer subjacente à manifestação clínica de THB. Conclusão: Nossos achados podem direcionar a investigação de anormalidades da SB em populações de alto risco para o desenvolvimento de THB, talvez como biomarcadores precoces antes da síndrome aberta.


Subject(s)
Humans , Male , Female , Adult , Bipolar Disorder/diagnostic imaging , White Matter/diagnostic imaging , Organ Size , Bipolar Disorder/pathology , Magnetic Resonance Imaging , Case-Control Studies , Disease Progression , Corpus Callosum/pathology , Corpus Callosum/diagnostic imaging , Gray Matter/pathology , Gray Matter/diagnostic imaging , White Matter/pathology , Middle Aged
6.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 40(2): 163-168, Apr.-June 2018. tab, graf
Article in English | LILACS | ID: biblio-959223

ABSTRACT

Objective: Cardiovascular disease is the leading cause of death in patients with bipolar disorder. The aim of this study was to evaluate the factors associated with positive coronary calcium score (CCS) in individuals with bipolar disorder type 1. Methods: Patients from the Bipolar Disorder Program at Hospital de Clínicas de Porto Alegre, Brazil, underwent computed tomography scanning for calcium score measurement. Clinical and sociodemographic variables were compared between patients according to their CCS status: negative (CCS = 0) or positive (CCS > 0). Poisson regression analysis was used to examine the association of CCS with number of psychiatric hospitalizations. Results: Out of 41 patients evaluated, only 10 had a positive CCS. Individuals in the CCS-positive group were older (55.2±4.2 vs. 43.1±10.0 years; p = 0.001) and had more psychiatric hospitalizations (4.7±3.0 vs. 2.6±2.5; p = 0.04) when compared with CCS- negative subjects. The number of previous psychiatric hospitalizations correlated positively with CCS (p < 0.001). Conclusion: Age and number of psychiatric hospitalizations were significantly associated with higher CCS, which might be a potential method for diagnosis and stratification of cardiovascular disease in bipolar patients. There is a need for increased awareness of risk assessment in this population.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Bipolar Disorder/complications , Coronary Artery Disease/diagnostic imaging , Cardiovascular Diseases/etiology , Risk Assessment/methods , Vascular Calcification/diagnostic imaging , Psychiatric Status Rating Scales , Time Factors , Coronary Artery Disease/complications , Cardiovascular Diseases/diagnostic imaging , Tomography, X-Ray Computed , Poisson Distribution , Cross-Sectional Studies , Predictive Value of Tests , Risk Factors , Analysis of Variance , Age Factors , Vascular Calcification/complications , Hospitalization/statistics & numerical data
7.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 40(2): 169-173, Apr.-June 2018. graf
Article in English | LILACS | ID: biblio-959225

ABSTRACT

Objective: N-acetylcysteine (NAC) is beneficial in psychiatric conditions, including schizophrenia. Patients with schizophrenia exhibit mesolimbic dopamine hyperfunction consequent to an endogenous sensitization process. This sensitization can be modeled in rodents by repeated exposure to psychostimulants, provoking an enduring amplified response at subsequent exposure. The aim of this study was to investigate the effects of NAC on amphetamine sensitization in mice. Methods: D-amphetamine was administered to C57BL/6 mice three times a week for 3 weeks; the dose was increased weekly from 1 to 3 mg/kg. NAC (60 mg/kg) or saline was administered intraperitoneally before saline or amphetamine during the second and third weeks. After a 4-week washout period, latent inhibition (LI) and the locomotor response to amphetamine 2 mg/kg were assessed. Results: Sensitization disrupted LI and amplified the locomotor response; NAC disrupted LI in control mice. In sensitized animals, NAC attenuated the enhanced locomotion but failed to prevent LI disruption. Conclusion: NAC warrants consideration as a candidate for early intervention in ultra-high risk subjects due to its safety profile and the relevance of its mechanism of action. Supplementing this proposition, we report that NAC attenuates sensitization-induced locomotor enhancement in mice. The finding that NAC disrupted LI incites a cautionary note and requires clarification.


Subject(s)
Animals , Male , Rats , Acetylcysteine/pharmacology , Schizophrenia/drug therapy , Behavior, Animal/drug effects , Central Nervous System Stimulants/pharmacology , Motor Activity/drug effects , Acetylcysteine/administration & dosage , Disease Models, Animal , Amphetamine/administration & dosage , Central Nervous System Stimulants/administration & dosage , Mice, Inbred C57BL
9.
Trends psychiatry psychother. (Impr.) ; 39(1): 43-47, Jan.-Mar. 2017. graf
Article in English | LILACS | ID: biblio-846398

ABSTRACT

Abstract Introduction: Transsexualism (ICD-10) is a condition characterized by a strong and persistent dissociation with one's assigned gender. Sex reassignment surgery (SRS) and hormone therapy provide a means of allowing transsexual individuals to feel more congruent with their gender and have played a major role in treatment over the past 70 years. Brain-derived neurotrophic factor (BDNF) appears to play a key role in recovery from acute surgical trauma and environmentally mediated vulnerability to psychopathology. We hypothesize that BDNF may be a biomarker of alleviation of gender incongruence suffering. Objectives: To measure preoperative and postoperative serum BDNF levels in transsexual individuals as a biomarker of alleviation of stress related to gender incongruence after SRS. Methods: Thirty-two male-to-female transsexual people who underwent both surgery and hormonal treatment were selected from our initial sample. BDNF serum levels were assessed before and after SRS with sandwich enzyme linked immunosorbent assay (ELISA). The time elapsed between the pre-SRS and post-SRS blood collections was also measured. Results: No significant difference was found in pre-SRS or post-SRS BDNF levels or with relation to the time elapsed after SRS when BDNF levels were measured. Conclusion: Alleviation of the suffering related to gender incongruence after SRS cannot be assessed by BDNF alone. Surgical solutions may not provide a quick fix for psychological distress associated with transsexualism and SRS may serve as one step toward, rather than as the conclusion of, construction of a person's gender identity.


Resumo Introdução: O transexualismo (CID-10) é uma condição caracterizada por forte e persistente dissociação com o gênero atribuído. A cirurgia de redesignação sexual (CRS) e a terapia hormonal (TH) permitem que indivíduos transexuais se sintam mais congruentes com seu gênero e, por isso, têm desempenhado papel importante nos últimos 70 anos. O fator neurotrófico derivado do cérebro (BDNF) parece desempenhar um papel fundamental na recuperação do trauma cirúrgico agudo e vulnerabilidade ambiental à psicopatologia. Nós hipotetizamos que o BDNF pode ser um biomarcador de alívio do sofrimento de incongruência de gênero pós-CRS. Objetivos: Mensurar os níveis séricos de BDNF no pré e pós-operatório em indivíduos transexuais como biomarcador de alívio de estresse relacionado à incongruência de gênero após a CRS. Métodos: Trinta e duas pessoas transexuais masculino para feminino submetidas a cirurgia e tratamento hormonal foram selecionadas de nossa amostra inicial. O nível sérico de BDNF foi avaliado antes e depois da CRS pela técnica ELISA. O tempo decorrido entre as coletas de sangue pré e pós-CRS foi medido. Resultados: Não houve diferença significativa nos níveis de BDNF pré e pós-CRS ou em relação ao tempo decorrido entre a CRS e a coleta. Conclusão: O alívio do sofrimento relacionado à incongruência de gênero pós-CRS não pode ser avaliado apenas pelo BDNF. Soluções cirúrgicas podem não fornecer uma solução rápida para o sofrimento associado ao transexualismo, e a CRS pode servir como um passo em direção à, em vez de conclusão da, construção da identidade de gênero de uma pessoa.


Subject(s)
Humans , Male , Female , Adult , Stress, Psychological/blood , Transsexualism/blood , Brain-Derived Neurotrophic Factor/blood , Sex Reassignment Surgery , Gender Dysphoria/blood , Postoperative Period , Transsexualism/surgery , Transsexualism/psychology , Transsexualism/drug therapy , Blood Chemical Analysis , Enzyme-Linked Immunosorbent Assay , Biomarkers/blood , HIV Infections/complications , HIV Infections/blood , Prospective Studies , Treatment Outcome , Hormone Replacement Therapy , Preoperative Period , Gender Dysphoria/surgery , Gender Dysphoria/psychology , Gender Dysphoria/drug therapy
10.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 38(4): 281-286, Oct.-Dec. 2016. tab, graf
Article in English | LILACS | ID: lil-798093

ABSTRACT

Objective: Bipolar disorder (BD) has been associated with increased rates of age-related diseases, such as type II diabetes, metabolic syndrome, osteoporosis, and cardiovascular disorders. Several biological findings have been associated with age-related disorders, including increased oxidative stress, inflammation, and telomere shortening. The objective of this study was to compare telomere length among participants with BD at early and late stages and age- and gender-matched healthy controls. Methods: Twenty-six euthymic subjects with BD and 34 healthy controls were recruited. Genomic DNA was extracted from peripheral blood and mean telomere length was measured using real-time quantitative polymerase chain reaction. Results: Telomere length was significantly shorter in both the early and late subgroups of BD subjects when compared to the respective controls (p = 0.002 and p = 0.005, respectively). The sample size prevented additional subgroup analyses, including potential effects of medication, smoking status, and lifestyle. Conclusion: This study is concordant with previous evidence of telomere shortening in BD, in both early and late stages of the disorder, and supports the notion of accelerated aging in BD.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Bipolar Disorder/genetics , Aging/genetics , Telomere/genetics , Telomere Shortening/genetics , Bipolar Disorder/physiopathology , DNA/blood , Case-Control Studies , Cellular Senescence/genetics , Real-Time Polymerase Chain Reaction
11.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 38(3): 201-206, July-Sept. 2016. tab, graf
Article in English | LILACS | ID: lil-792743

ABSTRACT

Objectives: Depressive symptoms are associated with worse outcomes in patients with bipolar disorder (BD). However, scarce data are available regarding neurocognitive profiles across different areas of functioning among BD patients with moderate and severe depression. Our objective was to assess cognition and global functioning in a group of patients with bipolar depression. Methods: Data were available for 100 patients with bipolar depression (78% female) and 70 controls (64% female) paired by age and education level. Cognitive function was assessed with a neuropsychological test battery. Functioning was assessed with the Functioning Assessment Short Test. Results: In patients, severe depression was associated with poorer cognitive performance on measures of executive function. Patients with severe depression showed worse global functioning than those with moderate depression (z = 2.54, p = 0.011). In patients with severe depression, lower global functioning was associated with lower scores in working memory (r = -0.200, p = 0.010), and executive function (r = -0.210, p = 0.007; and r = 0.293, p < 0.001). Conclusion: Our findings suggest cognitive impairment and global functioning impairment are associated with the severity of depressive symptoms in bipolar depression. Intensive treatment of depressive symptoms in patients with BD is crucial to improve cognitive functioning and, consequently, functional outcomes.


Subject(s)
Humans , Male , Female , Adult , Bipolar Disorder/physiopathology , Depression/physiopathology , Cognitive Dysfunction/physiopathology , Psychiatric Status Rating Scales , Severity of Illness Index , Case-Control Studies , Analysis of Variance , Cognition/physiology , Executive Function/physiology , Memory, Short-Term/physiology , Middle Aged , Neuropsychological Tests
12.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 38(2): 167-175, Apr.-June 2016. tab, graf
Article in English | LILACS | ID: lil-784303

ABSTRACT

Objective: To review the available data on diffusion tensor imaging (DTI) of subjects with bipolar disorder (BD), with a particular focus on fractional anisotropy (FA) in white matter (WM) tracts. Methods: The PubMed/MEDLINE database was searched for relevant articles, which were included in a systematic review of the literature. FA reductions and WM abnormalities were divided anatomically into three groups: commissural tracts, association tracts, and projection tracts. Results: Eighteen studies met the inclusion criteria. The corpus callosum was the main impaired commissural tract as demonstrated by FA reductions. Five studies reported FA reductions in the cingulum. Two studies reported decreased FA in the anterior thalamic radiation, and one in the corticospinal tract. Conversely, three studies found increased FA values in WM tracts involved in BD pathophysiology. Conclusion: Despite considerable heterogeneity, these results indicate a direct link between executive cognitive functioning and abnormal WM microstructural integrity of fronto-limbic tracts in patients with remitted BD, providing further evidence of the neuronal disruption that underlies BD symptomatology.


Subject(s)
Humans , Bipolar Disorder/diagnostic imaging , Diffusion Tensor Imaging , Bipolar Disorder/physiopathology , Anisotropy , Executive Function/physiology , White Matter/physiopathology , White Matter/diagnostic imaging , Neural Pathways/physiopathology
14.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 37(2): 121-125, 12/05/2015. tab, graf
Article in English | LILACS | ID: lil-748986

ABSTRACT

Objectives: Staging models for medical diseases are widely used to guide treatment and prognosis. Bipolar disorder (BD) is a chronic condition and it is among the most disabling disorders in medicine. The staging model proposed by Kapczinski in 2009 presents four progressive clinical stages of BD. Our aim was to evaluate pharmacological maintenance treatment across these stages in patients with BD. Methods: One hundred and twenty-nine subjects who met DSM-IV criteria for BD were recruited from the Bipolar Disorders Program at Hospital de Clínicas de Porto Alegre, Brazil. All patients were in remission. The subjects were classified according to the staging model: 31 subjects were classified as stage I, 44 as stage II, 31 as stage III, and 23 as stage IV. Results: Patterns of pharmacological treatment differed among the four stages (p = 0.001). Monotherapy was more frequent in stage I, and two-drug combinations in stage II. Patients at stages III and IV needed three or more medications or clozapine. Impairment in functional status (Functioning Assessment Short Test [FAST] scale scores) correlated positively with the number of medications prescribed. Conclusions: This study demonstrated differences in pharmacological treatment in patients with stable BD depending on disease stage. Treatment response can change with progression of BD. Clinical guidelines could consider the staging model to guide treatment effectiveness. .


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Anticonvulsants/administration & dosage , Antidepressive Agents/administration & dosage , Antipsychotic Agents/administration & dosage , Bipolar Disorder/drug therapy , Clozapine/administration & dosage , Bipolar Disorder/classification , Brazil , Clinical Protocols , Disease Progression , Evidence-Based Practice , Neuropsychological Tests , Practice Patterns, Physicians' , Psychiatric Status Rating Scales , Severity of Illness Index , Socioeconomic Factors
15.
Trends psychiatry psychother. (Impr.) ; 36(4): 209-213, Oct-Dec/2014. tab
Article in English | LILACS | ID: lil-731317

ABSTRACT

INTRODUCTION: Schizophrenia is frequently associated with a debilitating course and prominent impairment in social and occupational functioning. Although the criteria for classification into stages have not been defined in the literature, illness duration and functioning seem to be good candidates. OBJECTIVE: To compare functioning of patients with schizophrenia at different stages of the disease (early vs. late) and healthy sex- and age-matched controls. METHODS: This double-blinded, case-controlled study included 79 individuals: 23 patients with schizophrenia diagnosed up to 5 years earlier; 19 patients with schizophrenia diagnosed at least 20 years earlier; and healthy matched controls. Diagnoses were established using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) Axis I Disorder. Functioning was assessed using the Functioning Assessment Short Test (FAST). RESULTS: Patients in the early stage had significantly higher scores than healthy controls in total FAST and in autonomy, occupational functioning, cognitive functioning and interpersonal relationships. Individuals in the late stage had significantly poorer functioning than controls in all domains. The comparison of functioning between the two groups of patients revealed no significant differences, except in occupational functioning, in which late stage patients had a poorer performance. CONCLUSION: Functioning impairment in schizophrenia tends to remain stable despite illness duration. Therefore, functioning should be effectively assessed at an early stage, as illness duration alone may not be the most reliable criterion to stage patients with schizophrenia (AU)


INTRODUÇÃO: A esquizofrenia está frequentemente associada a um curso debilitante e a um importante comprometimento no funcionamento social e ocupacional. Embora os critérios para classificação em diferentes estágios ainda não tenham sido definidos, a duração da doença e a funcionalidade têm sido apontadas como bons candidatos. OBJETIVO: Comparar a funcionalidade de indivíduos com esquizofrenia no estágio inicial e final com controles saudáveis correspondentes em idade e sexo. MÉTODOS: Neste estudo caso-controle, duplo-cego, foram incluídos 79 pacientes: 23 com diagnóstico de esquizofrenia feito até 5 anos atrás (estágio inicial); 19 diagnosticados há pelo menos 20 anos (estágio final); e controles saudáveis pareados. O diagnóstico foi estabelecido pela Entrevista Clínica Estruturada para Transtornos do Eixo I do Manual Diagnóstico e Estatístico de Transtornos Mentais, 4ª edição (DSM-IV). A funcionalidade foi avaliada através da escala Teste Breve de Avaliação Funcional (FAST). RESULTADOS: Os pacientes em estágio inicial tiveram escores significativamente maiores do que controles saudáveis na escala FAST (escore total e domínios autonomia, funcionamento ocupacional, funcionamento cognitivo e relações interpessoais). Os indivíduos em estágio final apresentaram funcionalidade pior que os controles em todos os domínios. A comparação entre os dois grupos não mostrou diferenças, exceto no funcionamento ocupacional, em que os pacientes em estágio final apresentaram um desempenho pior. CONCLUSÃO: O prejuízo da funcionalidade na esquizofrenia tende a permanecer estável ao longo da doença. Portanto, a funcionalidade deve ser avaliada nos estágios iniciais da doença, já que a duração da doença por si só pode não ser o critério mais confiável para definir o estágio de pacientes com esquizofrenia (AU)


Subject(s)
Humans , Male , Female , Adult , Schizophrenia/classification , Schizophrenic Psychology , Social Adjustment , Psychiatric Status Rating Scales , Disability Evaluation
16.
Clin. biomed. res ; 34(1): 53-59, 2014. tab
Article in Portuguese | LILACS | ID: biblio-834450

ABSTRACT

INTRODUÇÃO: O Fator Neurotrófico Derivado do Cérebro (BDNF) é uma importante neurotrofina que está presente no tecido cerebral e periférico. O leite materno é considerado o alimento “padrão ouro” para o desenvolvimento cerebral, tornando o desmame precoce um fator de risco no desenvolvimento infantil. OBJETIVO: Avaliar a concentração de BDNF, IL6, IL10, TNF-α em crianças e correlacionar com a duração da amamentação. MÉTODOS: Trinta e sete crianças foram recrutadas e classificadas de acordo com a duração do aleitamento materno: < 6 meses (desmame precoce) e ≥ 6 meses. Foram realizadas duas consultas: a consulta basal em 2007 (T0) e a consulta de seguimento em 2011 (T1). Os níveis séricos de BDNF foram avaliados por ELISA sanduíche e os de citocinas por citometria de fluxo. RESULTADOS: Níveis séricos de BDNF em T0 foram significativamente menores no grupo amamentado por ≥ 6 meses (p=0,025), sendo que este não teve diferença entre os grupos em T1 (p=0,863). Níveis de IL6 apresentaram-se aumentados significativamente em T0 no grupo de desmame precoce (p=0,016). O IMC em T1 foi maior no grupo de desmame precoce (p=0,007). E em relação aos níveis de IL10 e TNF-α não houve diferenças significativas entre os grupos. CONCLUSÃO: Os resultados deste estudo mostraram semelhanças entre os níveis séricos de BDNF medidos a longo prazo, entre crianças amamentadas por < 6 meses e ≥ 6 meses, sugerindo que futuros estudos são necessários, com dosagens durante o período de amamentação para investigar o papel de marcadores neuroquímicos na duração do aleitamento materno e suas implicações no estado nutricional e cognição das crianças amamentadas.


BACKGROUND: The Brain-Derived Neurotrophic Factor (BDNF) is an important neurotrophin found in the brain and peripheral tissues. Breast milk is considered to be the “gold standard” food for brain development, making early weaning a risk factor in child development. AIM: To evaluate the concentration of BDNF, IL6, IL10, TNF-α in children and its correlation with the duration of breastfeeding. METHODS: Thirty-seven children were recruited and classified according to the duration of breastfeeding: <6 months (early weaning) and ≥ 6 months. There were two visits: the baseline interview in 2007 (T0) and the follow-up visit in 2011 (T1). BDNF levels were assayed using a sandwich ELISA, and cytokines were assayed with flow cytometry. RESULTS: Serum BDNF levels at T0 were significantly lower in the group breastfed for ≥ 6 months (p = 0.025), and they did not differ between groups at T1 (p = 0.863). IL-6 levels were significantly increased in the early weaning group at T0 (p = 0.016). Body mass index at T1 was higher in the early weaning group (p = 0.007). There was no significant difference in IL10 and TNF-α levels between groups. CONCLUSION: The results of this study showed similarities in serum BDNF levels over time between children who had been breastfed <6months and ≥ 6 months. This suggests that further studies, with measurements taken during the breastfeeding period, are needed to investigate the role of neurochemical markers in the duration of breastfeeding and its implications on nutritional status and cognition of breastfed children.


Subject(s)
Humans , Adolescent , Breast Feeding , Brain-Derived Neurotrophic Factor/blood , Milk, Human/physiology , Body Mass Index , Body Weight , Causality , Cytokines , Obesity/prevention & control , Time Factors
17.
Rev. AMRIGS ; 37(2): 88-92, abr.-jun. 1993. tab
Article in Portuguese | LILACS | ID: lil-193993

ABSTRACT

Este estudo visou a obtençäo de dados referentes ao comportamento sexual do adolescente em Porto Alegre, principalmente quanto à prevalência de atividade sexual nas escolas públicas e privadas e nos diferentes níveis sociais. Entrevistou-se 710 estudantes do segundo grau, de 14 a 19 anos de idade. Foram colhidos dados referentes ao nível sócio-econômico, idade da primeira relaçäo sexual, frequência das relaçöes sexuais, número de parceiros, frequência do uso de preservativos e número de relaçöes homossexuais. Houve relaçöes sexuais em 64,20 por cento dos rapazes e em 26,93 por cento das moças, sendo a idade média da primeira relaçäo, respectivamente, de 14,2 e 15,5 anos. A idade do primeiro coito foi similar em escolas públicas e privadas, assim como em níveis sócio econômicos superior e inferior. Considerou-se significante o p<0,05 e o intervalo de confiança utilizado foi de 0,036


Subject(s)
Humans , Adolescent , Adolescent Behavior , Sexual Behavior
SELECTION OF CITATIONS
SEARCH DETAIL